Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Institutional & Insider Ownership
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Cardiff Oncology and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 447.45%. Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 134.95%. Given Cardiff Oncology’s higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Monte Rosa Therapeutics.
Volatility & Risk
Cardiff Oncology has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Valuation and Earnings
This table compares Cardiff Oncology and Monte Rosa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $508,000.00 | 209.80 | -$45.85 million | ($0.60) | -2.28 |
| Monte Rosa Therapeutics | $28.73 million | 36.02 | -$38.63 million | ($1.76) | -6.89 |
Monte Rosa Therapeutics has higher revenue and earnings than Cardiff Oncology. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
